1-2 of 2 results for subject:Pfizer
Librarians' tools
- Search time
- 0.24 seconds
- Solr query time
- 0.002 seconds
- Search query
- subject:Pfizer
- We searched for
- subject_t:Pfizer OR subject_ses:61578
Subject
X
Cost effectiveness
Type
House
Session
Year
Department
Member
Primary member
Answering member
Legislative stage
Legislation
Subject
More
Cost effectiveness (2)
Publisher
Deposited by
Department of Health
Type
Deposited papers
Author
Department of Health
Committed on
6 September 2011
Received on
6 September 2011
Subjects
Children; Cost effectiveness; Health Protection Agency; Disease control; NHS; Research; Vaccination; Pfizer; Meningitis; Influenza; Joint Committee on Vaccination and Immunisation; Measles; Human papillomavirus; Novartis
Date
6 September 2011
Reference
DEP2011-1433
House
House of Commons
Type
House of Commons papers; Select Committee written evidence;
Parliamentary committees
Committee
Health Committee
Notes
Report printed as HC 27 2007-08
Subjects
Assessments; Companies; Cost effectiveness; Finance; Licensing; Drugs; NHS; Medical treatments; Patients; Prescription drugs; Public expenditure; Primary care trusts; Prices; National Institute for Health and Care Excellence; Standards; Technology; British Medical Association; Pfizer; Alzheimer's Society; National Osteoporosis Society; Multiple Sclerosis Society; Clinical trials; Royal College of Nursing; Bioindustry Association; British Psychological Society; Cancer Research UK; Diabetes UK; Hepatitis C Trust; British Association for Counselling and Psychotherapy; Help the Aged; Motor Neurone Disease Association; Royal College of Midwives; Amgen Roche; Association of British Healthcare Industries; AstraZeneca; Arthritis and Musculoskeletal Alliance; Breakthrough Breast Cancer; Cancerbackup; Continence Foundation; Cystic Fibrosis Trust; JEC; Medical Technology Group; National Infertility Awareness Campaign; National Childbirth Trust; Myalgic Encephalomyelitis Association; National Rheumatoid Arthritis Society; Royal College of Paediatrics and Child Health; Roche; Sanofi-Aventis; Wyeth; Academy of Medical Sciences; Roy Castle Lung Cancer Foundation; Specialised Healthcare Alliance; Medtronic; American Pharmaceutical Group; Archimedes Pharma; Beat; Bayer Schering Pharma; British Society for Rheumatology; Bristol Myers Squibb Pharmaceuticals; Deltex Medical; Eli Lilly; European Medicines Group; Ethical Medicines Industry Group; FEmISA; Improving Surgical Outcomes Group; Institute for Innovation and Valuation in Health Care; Kidney Cancer UK; Kinetic Concepts; Leukaemia Care; Merck; Myeloma UK; Pelvic Pain Support Network; Rarer Cancers Forum; Royal College of Physicians of Edinburgh; Sirtex Medical; Servier Laboratories; 25% ME Group; Meads, Catherine; Bouder, Frederic; Barkham, Michael; Lofstedt, Ragnar; Simkin, Sandra; Austin, Daphne; Jones, Doris; Hooper, Malcolm; Chalmers, Iain; Hyde, Chris; Lee, Gay; Evans, Imogen; Marshall, Tom; Lee, Michael; Telford, Peter; Walsh, John; Syrett, Keith; Thornton, Hazel; Thomson, David; Woodward, Rose
Date
26 April 2007
Reference
HC 503 2006-07
House
House of Commons